Atrial Fibrillation is the most common cardiac arrhythmia seen in clinical practice worldwide. The current pharmacological treatment is composed of rate control and rhythm control approaches. These are combined with anticoagulation to prevent thromboembolic events. Their clinical uses based on the presence or absence of structural heart disease and their side effects are discussed in this thesis.